Therini Bio Raises $36M Series A Financing
Summary
Therini Bio, a South San Francisco, CA-based biotech company that provides fibrin-targeted therapies, raised $36M in Series A funding. The company intends to use the funds to advance potential investigational antibody THN391 into clinical trials. Its lead antibody, THN391, binds the inflammation-driving component of fibrin that is known to activate immune responses in neurodegenerative and ophthalmologic diseases. Importantly, based on preclinical studies to date, targeting this region does not impact or diminish fibrin’s critical role in blood clotting and coagulation. Therini Bio was also awarded a $3M non-dilutive funding grant in 2021 from the National Institutes of Health (NIH) National Institute on Aging (NIA), which will provide $1M of preclinical research funding to advance the Company’s Alzheimer’s disease program each year through 2024.